A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs

Fungal Genetics and Biology

Volumn 49, Issue 11, 2012, Pages 955-966

  Kim, Jeongmi ^a   Cho, Yong Joon ^b   Do, Eunsoo ^a   Choi, Jaehyuk ^c,d   Hu, Guanggan ^c,d   Cadieux, Brigitte ^c,d   Chun, Jongsik ^b   Lee, Younghoon ^e   Kronstad, James W ^c,d   Jung, Won Hee ^a  

^a Chung Ang University   (South Korea)

^b Seoul National University   (South Korea)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Antifungal drugs; CFO1; Cryptococcus neoformans; Ferroxidase; Fluconazole; Iron uptake

Indexed keywords

DIPHENYLIODONIUM SALT; ERG11 PROTEIN; ERGOSTEROL; FLUCONAZOLE; FUNGAL ENZYME; IRON CHELATING AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOSYNTHESIS; CELL RESPIRATION; CFO1 GENE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DOWN REGULATION; DRUG POTENTIATION; FUNGAL GENE; FUNGAL METABOLISM; FUNGUS GROWTH; FUNGUS MUTANT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENETIC ANALYSIS; IRON CHELATION; IRON METABOLISM; IRON TRANSPORT; MITOCHONDRION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TRANSCRIPTOME ANALYSIS; WILD TYPE;

ANTIFUNGAL AGENTS; AZOLES; BIOLOGICAL TRANSPORT; CERULOPLASMIN; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; ERGOSTEROL; FLUCONAZOLE; FUNGAL PROTEINS; GENE DELETION; GENE EXPRESSION REGULATION, FUNGAL; HUMANS; IRON; MICROBIAL SENSITIVITY TESTS;

FILOBASIDIELLA NEOFORMANS;

EID: 84867911841     PISSN: 10871845     EISSN: 10960937     Source Type: Journal    
DOI: 10.1016/j.fgb.2012.08.006     Document Type: Article

References (49)

1. Ashburner M., et al. Gene ontology: tool for the unification of biology. Gene. Ontol. Consortium. Nat. Genet. 2000, 25:25-29.
2. Bammert G.F., Fostel J.M. Genome-wide expression patterns in Saccharomyces cerevisiae: comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol. Antimicrob. Agents Chemother. 2000, 44:1255-1265.
3. Barros M.H., et al. Higher respiratory activity decreases mitochondrial reactive oxygen release and increases life span in Saccharomyces cerevisiae. J. Biol. Chem. 2004, 279:49883-49888.
4. Bennett J.E., et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. New Engl. J. Med. 1979, 301:126-131.
5. Bicanic T., Harrison T.S. Cryptococcal meningitis. Br. Med. Bull. 2004, 72:99-118.
6. Clinical and Laboratory Standards Institute (CLSI), 2008. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, vol. 28, no. 14. Approved Standard M27-A3. National Committee for Clinical and Laboratory Standards, Villanova, Pa.
7. Cowen L.E., et al. Genetic architecture of Hsp90-dependent drug resistance. Eukaryot. Cell 2006, 5:2184-2188.
8. Cowen L.E., Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 2005, 309:2185-2189.
9. Du W., et al. Shuttle vectors for Candida albicans: control of plasmid copy number and elevated expression of cloned genes. Curr. Genet. 2004, 45:390-398.
10. Emanuelsson O., et al. Predicting subcellular localization of proteins based on their N-terminal amino acid sequence. J. Mol. Biol. 2000, 300:1005-1016.
11. Florio A.R., et al. Genome-wide expression profiling of the response to short-term exposure to fluconazole in Cryptococcus neoformans serotype A. BMC Microbiol. 2011, 11:97.
12. Ghannoum M.A., Rice L.B. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 1999, 12:501-517.
13. Giles S.S., et al. Cytochrome c peroxidase contributes to the antioxidant defense of Cryptococcus neoformans. Fungal. Genet. Biol. 2005, 42:20-29.
14. Hakim J.G., et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS 2000, 14:1401-1407.
15. Heilmann C.J., et al. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans. Antimicrob. Agents Chemother. 2010, 54:353-359.
16. Hoffbrand A.V., et al. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003, 102:17-24.
17. Ibrahim A.S., et al. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J. Antimicrob. Chemother. 2006, 58:1070-1073.
18. Ihrig J., et al. Iron regulation through the back door: iron-dependent metabolite levels contribute to transcriptional adaptation to iron deprivation in Saccharomyces cerevisiae. Eukaryot. Cell 2010, 9:460-471.
19. Jung W.H., et al. Role of ferroxidases in iron uptake and virulence of Cryptococcus neoformans. Eukaryot Cell 2009, 8:1511-1520.
20. Jung W.H., et al. HapX positively and negatively regulates the transcriptional response to iron deprivation in Cryptococcus neoformans. PLoS Pathog 2010, 6:e1001209.
21. Jung W.H., et al. Iron source preference and regulation of iron uptake in Cryptococcus neoformans. PLoS Pathog 2008, 4:e45.
22. Jung W.H., et al. Iron regulation of the major virulence factors in the AIDS-associated pathogen Cryptococcus neoformans. PLoS Biol. 2006, 4:e410.
23. Kobayashi D., et al. Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect. Antimicrob. Agents Chemother. 2002, 46:3113-3117.
24. Lepak A., et al. Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole. Antimicrob. Agents Chemother. 2006, 50:1311-1319.
25. Lin S.J., et al. Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev. 2004, 18:12-16.
26. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
27. Lupetti A., et al. Molecular basis of resistance to azole antifungals. Trends Mol. Med. 2002, 8:76-81.
28. Majander A., et al. Diphenyleneiodonium inhibits reduction of iron-sulfur clusters in the mitochondrial NADH-ubiquinone oxidoreductase (Complex I). J. Biol. Chem. 1994, 269:21037-21042.
29. Marchetti O., et al. Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob. Agents Chemother. 2000, 44:2932-2938.
30. Marchetti O., et al. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob. Agents Chemother. 2000, 44:2373-2381.
31. Mortazavi A., et al. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 2008, 5:621-628.
32. Philpott C.C., et al. Metabolic remodeling in iron-deficient fungi. Biochim. Biophys. Acta 2012.
33. Prasad T., et al. Unexpected link between iron and drug resistance of Candida spp.: iron depletion enhances membrane fluidity and drug diffusion, leading to drug-susceptible cells. Antimicrob. Agents Chemother. 2006, 50:3597-3606.
34. Puig S., et al. Coordinated remodeling of cellular metabolism during iron deficiency through targeted mRNA degradation. Cell 2005, 120:99-110.
35. Reverter-Branchat G., et al. Chronological and replicative life-span extension in Saccharomyces cerevisiae by increased dosage of alcohol dehydrogenase 1. Microbiology 2007, 153:3667-3676.
36. Rogers P.D., Barker K.S. Evaluation of differential gene expression in fluconazole-susceptible and -resistant isolates of Candida albicans by cDNA microarray analysis. Antimicrob. Agents Chemother. 2002, 46:3412-3417.
37. Sanglard D., et al. Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol. Microbiol. 2003, 48:959-976.
38. Schrettl M., et al. HapX-mediated adaption to iron starvation is crucial for virulence of Aspergillus fumigatus. PLoS Pathog 2010, 6:e1001124.
39. Schroeder A., et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol. 2006, 7:3.
40. Shakoury-Elizeh M., et al. Metabolic response to iron deficiency in Saccharomyces cerevisiae. J. Biol. Chem. 2010, 285:14823-14833.
41. Shi Y., et al. Human ISD11 is essential for both iron-sulfur cluster assembly and maintenance of normal cellular iron homeostasis. Hum. Mol. Genet. 2009, 18:3014-3025.
42. Singh S.D., et al. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog 2009, 5:e1000532.
43. Sionov, E., et al., 2011. Identification of a Cryptococcus neoformans Cytochrome P450 Lanosterol 14alpha-Demethylase (Erg11) Residue Critical for Differential Susceptibility between Fluconazole/Voriconazole and Itraconazole/Posaconazole. Antimicrob. Agents Chemother.
44. Sionov E., et al. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog 2010, 6:e1000848.
45. Toffaletti D.L., et al. Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. J. Bacteriol. 1993, 175:1405-1411.
46. Wallace M.A., et al. Superoxide inhibits 4Fe-4S cluster enzymes involved in amino acid biosynthesis. Cross-compartment protection by CuZn-superoxide dismutase. J. Biol. Chem. 2004, 279:32055-32062.
47. Wirk B., Wingard J.R. Combination antifungal therapy: from bench to bedside. Curr. Infect Dis. Rep. 2008, 10:466-472.
48. Zarember K.A., et al. Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus. Antimicrob. Agents Chemother. 2009, 53:2654-2656.
49. Zonios D.I., Bennett J.E. Update on azole antifungals. Semin Respir Crit. Care Med. 2008, 29:198-210.